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direct role of GNRH-I on corpora lutea (CL) function were
studied in the pseudopregnant rabbit model. Immunohisto-
chemistry evidenced GNRHR-I and GNRH-I in luteal cells at
early (day 4 pseudopregnancy)-, mid (day 9)-, and late (day 13)-
luteal stages. Real-time RT-PCR and western blotting revealed
GNRHR-I mRNA and protein at the three luteal stages.
Buserelin in vivo treatment at days 9 and 13 decreased plasma
progesterone levels for 48 and 24 h respectively. In in vitro
cultured CL, buserelin reduced progesterone secretion,
increased prostaglandin F2a (PGF2a) secretion and cyclo-
oxygenase-2 (COX-2) and nitric oxide synthase (NOS)
activities at days 9 and 13, and decreased PGE2 at day 13.
Co-incubation with antagonists for GNRH-I (antide), inositol
1,4,5-trisphosphate (IP3, 2-amino-ethoxydiphenylborate), andJournal of Endocrinology (2010) 207, 289–300
0022–0795/10/0207–289 q 2010 Society for Endocrinology Printed in Greatdiacylglycerol (DAG, 1-hexadecyl-2-acetyl glycerol) or
inhibitors for phospholipase C (PLC, compound 48/80), and
protein kinase C (PKC, staurosporine) counteracted the
buserelin effects. Buserelin co-incubated with COX inhibitor
(acetylsalicylic acid) increased progesterone and decreased
PGF2a and NOS activity at days 9 and 13, whereas
co-incubation with NOS inhibitor (N-nitro-L-arginine methyl
ester) increased progesterone at the same luteal stages. These
results suggest that GNRHR-I is constitutively expressed in
rabbit CL independently of luteal stage, whereas GNRH-I
down-regulates directly CL progesterone productionvia PGF2a
at mid- and late-luteal stages of pseudopregnancy, utilizing its
cognate type I receptor with a post-receptorial mechanism that
involves PLC, IP3, DAG, PKC, COX-2, and NOS.
Journal of Endocrinology (2010) 207, 289–300Introduction
GNRH is a hypothalamic neuronal secretory decapeptide
that plays a central regulatory role in mammalian reproductive
physiology. GNRH influences reproductive processes mainly
by regulating pituitary gonadotropin synthesis and release,
which in turn modulate steroidogenesis and gametogenesis
(Conn & Crowley 1994). Even if the hypothalamus and
pituitary are, respectively, the principal source of and target
site for GNRH, several studies have reported an extra-
hypothalamic origin of GNRH, as well as an extrapituitary
presence of GNRH receptor (GNRHR) in numerous
peripheral tissues including reproductive organs, such as
testis, prostate, ovary, oviduct, placenta, and mammary gland
(Ramakrishnappa et al. 2005).
There are currently 14 identified naturally occurring
GNRH structural variants across the vertebrate species
(Somoza et al. 2002). However, it is evident that at least
three forms of GNRH are present in the majority of the
vertebrate species studied: hypothalamic GNRH (GNRH-I),mid-brain GNRH (GNRH-II), and telencephalic GNRH
(GNRH-III) (Gorbman & Sower 2003). In extrapituitary
reproductive tissues, GNRH is considered to act in an
autocrine or a paracrine manner and to regulate ovarian
steroidogenesis by exerting a stimulatory as well as an
inhibitory effect on the production of steroid hormones and
apoptosis in ovarian follicles and corpora lutea (CL; Dubois
et al. 2002, Ramakrishnappa et al. 2005). Although three types
of GNRHR have been identified thus far, mammals have
only two types of receptors: GNRHR-I and -II (Millar
2005). All known GNRHRs are transmembrane G protein-
coupled receptors that produce their effects by activating
phospholipase A2 (PLA2), phospholipase C (PLC), PLD, or
adenylate cyclase (AC) cell signaling pathways (Millar 2005).
Phospholipase activation may generate arachidonic acid (AA)
that is converted into prostaglandins (PGs) by the action of the
cyclo-oxygenase-1 and -2 (COX-1 and -2) as well as by that
of other PG synthase enzyme types (Naor 2009).
Various studies have shown that GNRH exerts both
inhibitory and stimulatory effects in the gonads, with eitherDOI: 10.1677/JOE-10-0109
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production (Ramakrishnappa et al. 2005). Few studies have
addressed the direct effects of GNRH in rabbit CL, with
conflicting results: earlier works pointed to CL regression
with serum progesterone decline (Hilliard et al. 1976, Rippel
et al. 1976), while a later study indicated that there was no
effect on steroid production by ovary cultured in vitro
(Eisenberg et al. 1984). Therefore, the main objectives of
the present study were to examine the in vivo and in vitro
modulatory effects of GNRH on rabbit CL during early-,
mid-, and late-luteal stages of pseudopregnancy. With this end
in view, experiments were devised to clarify the presence of
GNRHR-I and GNRH-I and their possible post-receptorial
mechanisms, as well as the effects of GNRH-I on the
production of progesterone, PGE2, and PGF2a and on the
activities of COX-1 and -2 and nitric oxide synthase (NOS),
the enzymes involved in the regulation of rabbit CL life span
(Boiti et al. 2000, 2005, Zerani et al. 2007).Materials and Methods
Reagents
Reagent for isolation of total RNA (TRIzol) was purchased
from Invitrogen. iSCRIPT cDNA and iQ SYBR Green
SuperMix were purchased from Bio-Rad. QIAquick PCR
Purification Kit for sequencing PCR product was from
Qiagen. Random hexamer primers, DNase I Amplification
Grade, real-time PCR primers for GNRHR-I and 18S were
supplied by Invitrogen.
Tritiated progesterone, PGF2a, PGE2, and AA were
purchased from Amersham Biosciences Ltd, while non-
radioactive hormones and specific antisera were from Sigma–
Aldrich. The NOS detect TM assay kit was purchased from
Alexis Corp. (La¨ufelfingen, Germany).
Goat polyclonal anti-GNRHR-I primary antibody
(sc-8681) and biotin rabbit anti-goat IgG secondary antibody
(sc-2774) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Mouse monoclonal anti GNRH-I
primary antibody (MAB 5456) was purchased by Chemicon
International (Temecula, CA, USA) and biotin goat anti-
mouse IgG secondary antibody was obtained by Zymed
Laboratories (South San Francisco, CA, USA). The avidin–
biotin complex (ABC, Vector Elite Kit) and the chromogen
3,3 0-diaminobenzidine tetrachloride (DAB) were purchased
from Vector Laboratories (Burlingame, CA, USA). The
mouse monoclonal anti-b-tubulin antibody was from
Sigma–Aldrich. PageRuler Ladder for western blot (WB)
analysis was obtained from Fermentas (Burlington, Ontario,
Canada). The enhanced chemiluminescence detection system
for WB (Immobilon Western Chemiluminescent HRP
Substrate) was purchased from Millipore (Billerica, MA,
USA). The HRP-conjugated rabbit anti-goat IgG antibody
as well as the Restore Western Blot Stripping Buffer was
obtained from Thermo Fisher Scientific (Rockford, IL, USA).Journal of Endocrinology (2010) 207, 289–300The Protran nitrocellulose membranes were from Whatman
(Dassel, Germany). Biomax film for chemiluminescent blot
imaging was from Kodak Laboratories. The bands were
quantified using Quantity One software (Bio-Rad Laboratories).
The kit for the protein assay was purchased from Bio-Rad
Laboratories. Medium 199 and Earle’s Balanced Salt Solution
were from Gibco. HEPES, BSA, buserelin, antide, eCG,
4-bromophenacyl bromide, compound 48/80, propranolol,
2-O-methyladenosine, acetylsalicylic acid (ASA), and
N-nitro-L-arginine methyl were purchased from Sigma,
2-amino-ethoxydiphenylborate was from Tocris Cookson
Ltd (Northpoint Fourth Way Avonmouth, UK), and
1-hexadecyl-2-acetyl glycerol was from Biomol Research
Laboratories (Plymouth Meeting, PA, USA), whereas all
other pure grade chemicals and reagents were obtained locally.Animals and hormonal regimen
Sexually mature New Zealand White female rabbits
(3.5–4 kg body weight and 5 months of age) raised in
premises owned by the University of Perugia were used for all
experiments. The rabbits were housed individually in wire
mesh cages under controlled light (14 h light:10 h darkness;
lights off at 2100 h) and temperature (18–24 8C) conditions.
Each animal had free access to food and water. Pseudopreg-
nancy was induced with 20 IU eCG followed by 0.8 mg
buserelin 3 days later (Stradaioli et al. 1997). The day of
buserelin injection was designated as day 0. The animals (nZ5
for each luteal stage) were killed by cervical dislocation in
accordance with the guidelines and principles for the care and
use of research animals. The protocols involving the use of the
animals for these experiments were approved by the Bioethic
Committee of the University of Perugia.Tissue collection
Upon killing, reproductive tracts were promptly removed and
thoroughly washed with saline. Within a few minutes, the CL
were excised from ovaries and, after careful dissection of
non-luteal tissue by fine forceps under stereoscopic magni-
fication, immediately processed for in vitro experiments or
frozen atK80 8C, after rinsing with RNase-free PBS, for later
evaluation of gene and protein expression. For the immuno-
histochemical detection of GNRHR-I and GNRH-I, the
ovaries of two additional animals for each luteal stage were
fixed by immersion in 4% (w/v) formaldehyde in PBS (pH
7.4) for 24 h at room temperature, and subsequently processed
for embedding in paraffin following routine tissue preparation
procedures. The pituitary gland of a control rabbit was taken
and processed as described above.Immunohistochemistry
Tissue sections were deparaffinized in xylene, rehydrated
through graded ethanol, and finally rinsed in distilled water;
then they were submitted to antigen retrieval bywww.endocrinology-journals.org
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at 700 W for 10 min. The slides were cooled at room
temperature. After rinsing with Tris-buffered saline (TBS),
the specimens were dipped in 3% H2O2 (v/v) in methanol
for 1 h to quench the endogenous peroxidase activity and
rinsed in TBS. Background labeling was prevented by
incubating the sections with normal rabbit serum (for
GNRHR-I) and normal goat serum (for GNRH-I),
diluted 1:10, for 30 min at room temperature. Sub-
sequently, the sections were incubated for 1 h at 37 8C
and then overnight at 4 8C in a moist chamber with goat
polyclonal anti-GNRHR-I primary antibody, raised against
18 C-terminal residues, diluted 1:200 in TBS containing
0.1% BSA, whereas the ovary sections were treated also
with mouse monoclonal anti-GNRH primary antibody
diluted as described above. The next day, the slides were
rinsed three times in TBS for 5 min each, treated again
with normal serum and then incubated for 30 min at
room temperature with biotin rabbit anti-goat (for
GNRHR-I) or biotin goat anti-rabbit (for GNRH-I)
secondary antibodies diluted 1:200 in TBS. After TBS
washes, the slides were exposed to ABC for 30 min and
rinsed again with TBS. The peroxidase activity sites were
visualized using DAB kit as chromogen; then the specimens
were rinsed twice with distilled water for 5 min each,
counterstained with hematoxylin, washed in running tap
water and, finally, dehydrated passing through graded
ethanol (70, 95, and 100% v/v), cleared in xylene and
mounted with medium for light microscopy. Tissue sections
in which the primary antibody was omitted or substituted
by goat or mouse IgG were used as negative controls of
non-specific staining. Pituitary tissue sections from a
control rabbit were included as positive controls for the
GNRHR-I reaction. The intensity of GNRHR-I and
GNRH-I immunostaining in follicles and CL was assessed
and compared microdensitometrically. The image analysis
system (IAAS 2000 image analyzer, Delta Sistemi, Rome,
Italy) was calibrated by taking the background developed
in sections incubated with non-immune serum as ‘zero’ and
a conventional value of maximum intensity of staining
(Tomassoni et al. 2010) as ‘100’. Data are expressed in
arbitrary units.Table 1 Primers used for gene quantification by real-time PCR
Gene Accession number
GNRHR-I AY781779 Oryctolagus cuniculus Forw
Reve
FSHR AY429104.1 Homo sapiens Forw
Reve
LHR S57793 Homo sapiens Forw
Reve
18S X03205.1 Homo sapiens Forw
Reve
www.endocrinology-journals.orgGNRHR-I, FSHR, and LHR real-time RT-PCR
Total RNA was extracted from CL of three rabbits for each
luteal stage as described previously (Boiti et al. 2005).
According to the protocol provided by the manufacturer,
5 mg total RNA were reverse transcribed in 20 ml of iSCRIPT
cDNA using random hexamer. Genomic DNA contami-
nation was checked by developing the PCR without reverse
transcriptase. Serial experiments were performed to optimize
the quantitative reaction, efficiency, and threshold cycle (Ct)
values. The optimal 25 ml PCR volume contained 12.5 ml iQ
SYBR Green SuperMix, 1 ml forward and reverse primers
(stock concentration 10 mmol/l), and 25 ml water. The
primers used are listed in Table 1. All reagents were mixed
as a master mix and distributed into a 96-well PCR plate
before adding 2 ml cDNA (diluted 10-fold with water). For
every PCR run were included reaction controls without
template, as negative controls, and control without reverse
transcriptase in RT, to assess whether the RNA was free by
genomic DNA contamination. Samples’ amplification fidelity
was also verified by agarose gel electrophoresis. PCR was
performed on iCycler iQ (Bio-Rad) with an initial
incubation at 95 8C for 1.5 min, followed by 40 cycles at
95 8C for 15 s, 53 8C for 30 s, during which fluorescence data
were collected. The Ct value of each trace was automatically
computed. PCR products were purified and sequenced by
Qiaquick PCR Purification Kit according to the manu-
facturer’s protocol. The 18S Ct housekeeping gene, was
determined to normalize sample variations in the amount
of starting cDNA. Standard curves generated by plotting the
Ct value against the log cDNA standard dilution (1/10
dilution) in nuclease-free water were used to compare the
relative amount of target genes. The slope of this graph was
used to determine the reaction efficiency. Quantification of
mRNA samples was performed by iCycler system software.
The melting curve analysis, performed immediately after the
PCR end cycle, was used to determine the specificity of
each primer set. A melt-curve protocol was performed by
repeating 80 8C heating for 10 s, from 55 8C with 0.5C
increments, during which fluorescence data were collected.
The melting temperatures of the products were determined
graphically with fluorescence change rate (d(RFU)/dT)
versus temperature.bp Primers
ard 191 TGATCCACCTCACAAATGGA
rse ATGAAGGACCCGTGTCAGAG
ard 150 GAGGAATGCCATTGAACTGAGG
rse GGAAGGTTGGAGAACACATCTG
ard 118 CTGGAGAAGATGCACAATGG
rse CAATTAGCCTCTGAATGGACTC
ard 148 CGATCAGATACCGTCGTAGT
rse TTCCTTTAAGTTTCAGCTTTGC
Journal of Endocrinology (2010) 207, 289–300
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Total luteal proteins were extracted from a pool of ten CL
of three rabbits for each luteal stage. The CL were
homogenized in 1 ml ice-cold RIPA buffer (PBS
containing 1% Igepal CA-630, 0.5% sodium deoxycholate,
0.1% SDS v/v) as described previously (Zerani et al. 2004).
After incubation at 4 8C for 20 min, the homogenates were
centrifuged at 12 000 g for 60 min at 4 8C. The super-
natants were collected, and their protein concentrations
were measured using the protein assay kit with BSA as a
standard. Equal amounts of proteins (20 mg) were separated
by discontinuous 10% SDS-PAGE (w/v) with 4% stacking
gel (w/v) for 40 min at 200 V and 500 mA, after which
proteins were transferred onto a nitrocellulose membrane
for 1 h at 100 V and 350 mA. After the transfer, non-
specific binding of antiserum was prevented by incubation
with 0.05% Tween-20 (v/v), 5% non-fat dry milk (w/v),
and 5% BSA (w/v) in TBS. Blocked membranes were
then probed with antibody against GNRHR (1:500)
overnight at 4 8C. After washing with TBS, the membranes
were incubated with HRP-labeled rabbit anti-goat IgG
secondary antibody (1:20 000) at room temperature for 1 h.
All antibody incubations were performed in TBS
containing 5% BSA (w/v) and 0.05% Tween-20 (v/v).
After washing with TBS, the immunocomplexes were
visualized by using an enhanced chemiluminescence
detection kit according to the manufacturer’s protocol
and exposed to X-ray film. Blot images were acquired, and
the intensities of the bands were quantified by densito-
metric analysis using Quantity One software (Bio-Rad
Laboratories). Membranes were then reblotted with mouse
anti-b-tubulin monoclonal antibody (0.05 mg/ml) and
processed as described above to verify equal loading of
proteins. Data were normalized by reference to b-tubulin
after membrane stripping for 15 min with stripping
solution. Values were expressed as arbitrary units of relative
abundance of the specific protein normalized with that of
b-tubulin used as a loading control.Control 1 10 50 100 200 500 1000
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Figure 1 Invitroeffectsof increasingconcentrationsofGNRH-I agonist
(buserelin) on progesterone release by rabbit CL collected at day 9 of
pseudopregnancy. Values are meansGS.D. of five replicates. Asterisks
indicate a significantly different value (P!0.01) versus control.In vivo experiments
At days 4, 9, and 13 of pseudopregnancy, two groups of
rabbits (nZ6/group per day) were treated i.m. with either
saline (0.2 ml) or buserelin (0.8 mg). From each rabbit, blood
samples were collected by venipuncture of the marginal ear
vein 0, 24, and 48 h after injection. The samples, collected in
EDTA vacutainers, were centrifuged at 3000 g for 15 min,
and the frozen plasma was stored until assayed for
progesterone concentrations to assess the functional status of
the ovarian CL. For the purposes of this work, functional
luteolysis was defined as a 50% decrease in plasma
progesterone from pre-treatment values, while complete
luteolysis as the failure of CL to secrete progesterone so that
blood levels fall below 1.0 ng/ml, which are found in estrous
rabbits (Browning et al. 1980).Journal of Endocrinology (2010) 207, 289–300In vitro experiments
A method reported previously was used for the in vitro study
(Boiti et al. 2001). Day 4, 9, or 13 CL were randomly
distributed (one CL/well) into incubation wells (Becton
Dickinson Co., Clifton, NJ, USA) in 1 ml culture medium
199 with Earle’s Balanced Salt Solution containing 2.2 mg/ml
sodium bicarbonate, 2.3 mg/ml HEPES, and 3% BSA (w/v),
referred to here as M199. Before treatment, the CL were
quartered inside each well using fine forceps. Each set of
incubation wells was divided into 12 experimental groups,
each were formed of five wells as follows: I) medium alone as
control; II) GNRH-I agonist (buserelin, 200 nmol/l); III)
buserelinCGNRH-I antagonist (antide, 100 nmol/l); IV)
buserelinCPLA2 inhibitor (4-bromophenacyl bromide,
2 mmol/l); V) buserelinCPLC inhibitor (compound 48/80,
2 mmol/l); VI) buserelinCPLD inhibitor (propranolol,
10 mmol/l); VII) buserelinCAC inhibitor (2-O-methylade-
nosine, 2 mmol/l); VIII) buserelinCinositol 1,4,5-trispho-
sphate (IP3) antagonist (2-aminoethyl diphenylborinate,
100 mmol/l); IX) buserelinCdiacylglycerol (DAG) antagonist
(1-hexadecyl-2-acetyl glycerol, 100 mmol/l); X) buserelinC
protein kinase C (PKC) inhibitor (staurosporine 20 mmol/l);
XI) buserelinCCOX inhibitor (ASA, 100 mmol/l); XII)
buserelinCNOS inhibitor (N-nitro-L-arginine methyl ester,
100 mmol/l). The culture plates were incubated at 37 8C in air
with 5% CO2. The media of each well were collected after
4 h of incubation and stored immediately atK20 8C for later
determination of progesterone, PGF2a, and PGE2. Pre-
liminary evidence led us to choose the incubation conditions
and the minimum effective dose for buserelin used in the
present in vitro study (Fig. 1).Hormone determination
Progesterone, PGF2a, and PGE2 were determined following
the RIA protocols reported previously (Boiti et al. 2001).
Intra- and inter-assay coefficients of variation and minimumwww.endocrinology-journals.org
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Figure 2 Immunostaining for GNRHR-I of rabbit ovaries during the mid stage of pseudopregnancy. (a) The immunopositivity
is evident in the cytoplasm of luteal cells (L) and endothelial cells (arrows), (insert: control section in the absence of primary
antibody); (b) immunosignals are detected in the ooplasm of oocytes (O) and cytoplasm of follicular (F), thecal cells (T), and
endocrine interstitial cells (I) present in antral follicles, (insert: control section); (c) the immunolabeling is localized in the
ooplasm of oocytes (O) and cytoplasm of follicular (F) and thecal cells (T) present in pre-antral follicles; (d) immunosignals are
evident in the ooplasm of oocytes and cytoplasm of follicular cells present in primordial follicles (arrow) and in ovarian
epithelium (arrowhead), (insert: control section); (e) rabbit pituitary gland: cell groups show an intense immunoreactivity for
GNRHR-I. Scale barZ20 mm. Full colour version of this figure available via http://dx.doi.org/10.1677/JOE-10-0109.
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and 12%, 19 pg; PGE2: 7 and 13%, 18 pg.Enzyme activity determination
Luteal COX-1 and -2 activities were determined by
measuring the disappearance of the radiolabeled substrate
[3H]AA using a method reported previously (Zerani et al.
2007). Selective COX-2 inhibitor (NS-398 1 mmol/l) and
non-selective COX inhibitor (ASA, 1 mmol/l) were used.
For each sample, COX-1 activity was determined by
calculating the rate of loss of [3H]AA incubated with selective
COX-2 inhibitor. Conversely, the COX-2 activity of each
corresponding sample was determined by calculating the rate
of loss of [3H]AA incubated without selective COX-2
inhibitor and subtracting from this value that of COX-1.
The values for COX-1 and -2 were corrected by subtracting
the [3H]AA disappearance values due to other enzymatic
activities and to non-enzymatic reactions.
NOS activity was determined by monitoring the conver-
sion of [3H]L-arginine to [3H]L-citrulline with a commercial
NOS assay kit, according to the experimental protocol
described by Boiti et al. (2000).(a)
Statistical analysis
Data on gene and protein expressions, hormone levels, and
enzyme activities were examined by ANOVA followed by the
Student–Newman–Keuls t-test. Differences were considered
significant at P!0.01.(b) (c)
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Figure 3 Immunostaining for GNRH-I of rabbit ovaries during the
mid stage of pseudopregnancy. (a) Immunosignals are intensely
evidenced in the cytoplasm of luteal cells; the endothelial cells
(arrows) are immunolabeled; (b) the cytoplasm of follicular (F) and
thecal cells (TC) and the ooplasm (O) within antral follicles are
intensely immunopositive; the ovarian epithelium is strongly
immunostained; insert, control section in which the primary
antibody was omitted does not evidence immunopositivity at any of
the sites described for GNRH-I; (c) the follicular cells (F) and the
ooplasm (O) within pre-antral and primordial follicles are intensely
immunostained; note the immunopositivity of the connective tissue
present in the ovarian cortical cells (arrows). Scale barZ20 mm. Full
colour version of this figure available via http://dx.doi.org/10.1677/
JOE-10-0109.Results
GNRHR-I and GNRH-I immunolocalization
GNRHR-I Immunopositivity for GNRHR-I was detected
in the cytoplasm of luteal cells and endothelial cells (Fig. 2,
photo a); additionally, it was detected in the ooplasm of
oocytes and cytoplasm of follicular and thecal cells present
both in antral and pre-antral follicles (Fig. 2, photos b and c).
Immunosignals were also evident in the ooplasm of oocytes
and cytoplasm of follicular cells present in primordial follicles
(Fig. 2, photo d), ovarian epithelium (Fig. 2, photo d), and
endocrine interstitial cells (Fig. 2, photo a). The intervening
fibroblast cells within the CL were always unreactive.
Differences in the presence and intensity of immunostaining
were not observed during the three luteal stages. The control
staining procedure failed to disclose appreciable reactivity at
any of the sites described for GNRHR (inserts of Fig. 2,
photos a, b and d). The cytoplasm of pituitary cells exhibited
intense immunostaining (Fig. 2, photo e). In the ovary
collected at day 4 of pseudopregnancy, the intensity of
GNRHR-I immunostaining was higher in CL than in
follicles (39.92G5.46 and 29.53G3.99 respectively,Journal of Endocrinology (2010) 207, 289–300P!0.01), whereas no differences were found in the ovaries
at later stages of pseudopregnancy (data not shown).
GNRH-I Positive immunosignals for GNRH-I were
evidenced in the cytoplasm of luteal cells at all stages of
pseudopregnancy (Fig. 3, photo a). The cytoplasm of
follicular and thecal cells and the ooplasm within antral
follicles were immunopositive (Fig. 3, photo b) as well as
the follicular cells and the ooplasm within pre-antral and
primordial follicles (Fig. 3, photo c). The ovarian epithelium
(Fig. 3, photo b), endothelial cells (Fig. 3, photo a), and
interstitial cells displayed an intense immunoreactivity. The
connective tissue within the CL was not immunostained,
whereas that of the ovarian cortex immunoreacted to
GNRH-I (Fig. 3, photo c). The control sections were not
stained at any sites examined for GNRH-I (insert of Fig. 3,
photo b). The intensity of GNRH-I immunostaining did
not show any difference between CL and follicles at any luteal
stage considered (data not shown).www.endocrinology-journals.org
BDC
Day 4 CL Day 9 CL Day 13 CL
GNRHR-I
70 kDa
 
β-Tubulin
50 kDa
50 bp
150 bp
La
dd
er
w
/o
te
m
pl
at
e
w
/o
R
T G
NR
H
R-
I
19
1 
bp
18
S
14
8 
bp
A
4 9 13
Days of pseudopregnancy
0·0
0·5
1·0
1·5
2·0
2·5
3·0
3·5
A
rb
itr
ar
y 
flu
or
es
ce
nt
 u
ni
ts
4 9 13
Days of pseudopregnancy
0·0
0·1
0·2
0·3
0·4
G
nR
H
R-
1/
β-t
ub
ul
in
ar
bi
tra
ry
 u
ni
ts
Figure 4 (A) Gene expression of GNRHR-I mRNA in CL of rabbits
collected at days 4, 9, and 13 of pseudopregnancy. Representative
agarose gel electrophoresis stained with ethidium bromide to verify
matching between expected and obtained PCR products. For every
PCR, two negative controls were included, without template and
without reverse transcriptase respectively. (B) The values, expressed
in arbitrary fluorescence units related to 18S, are meansGS.D. of
four independent replicates. (C) Immunoblot showing GNRHR-I in
luteal CL lysates collected at days 4, 9, and 13 of pseudopregnancy.
Total protein extracts were separated by SDS gel electrophoresis
and analyzed by immunoblotting with GNRHR-I-specific antibody.
(D) Densitometric analysis of bands corresponding to GNRHR-I
after WB. Values of GNRHR-I protein bands were standardized to
those of b-tubulin. The results are meansGS.D. of four independent
experiments.
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FSHR, and LHR
GNRHR-I transcript was expressed in CL at different
stages of pseudopregnancy with no changes in its relative
abundance (Fig. 4, panels A and B). The protein abundance
of GNRHR-I did not differ between days 4, 9, and 13 of
pseudopregnancy (Fig. 4, panels C and D). The expressions
of FSHR and LHR transcripts were higher (P!0.01) in
day 13 CL than in day 4 and 9 CL (Fig. 5).4 9 13
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Figure 5 (A) Gene expressions of FSH and LH mRNA in CL ofIn vivo experiments
Buserelin administration at days 9 and 13 of pseudopregnancy
decreased (P!0.01) the peripheral plasma progesterone
concentrations for 48 and 24 h respectively (Fig. 6), whereas
buserelin injection at day 4 did not affect progesterone levels
(Fig. 6, panel B).
rabbits collected at days 4, 9, and 13 of pseudopregnancy.
Representative agarose gel electrophoresis stained with ethidium
bromide to verify matching between expected and obtained PCR
products. For every PCR, two negative controls were included,
without template and without reverse transcriptase respectively.
(B) The values, expressed in arbitrary fluorescence units related to
18S, are meansGS.D. of four independent replicates. Different letters
above the bars indicate significantly different values (P!0.01).In vitro experiments
Hormone releases Basal in vitro progesterone secretion was
higher in day 9 CL (P!0.01) than in day 4 and 13 CL,
secretion in day 13 CL was higher (P!0.01) than in day 4 CLwww.endocrinology-journals.org(Fig. 7, top panel). Buserelin reduced (P!0.01) progesterone
in vitro secretion by both day 9 and 13 CL, but had no effect
on day 4 CL (Fig. 7, top panel). The co-incubation of
buserelin with antide, compound 48/80, 2-aminoethyl
diphenylborinate, 1-hexadecyl-2-acetyl glycerol, or
staurosporine counteracted (P!0.01) the effects of buserelin
alone on day 9 and 13 CL (Fig. 7, top panel). The
co-treatments with ASA or N-nitro-L-arginine methyl ester
inhibitor increased (P!0.01) progesterone secretion by both
day 9 and 13 CL (Fig. 7, top panel). The co-treatment with
4-bromophenacyl bromide, propranolol, or 2-O-methylade-
nosine did not affect the buserelin-decreased progesterone
secretion on day 9 and 13 CL (data not shown).
Basal in vitro PGF2a secretion was higher in day 13 CL
(P!0.01) than in day 4 and 9 CL, and secretion in day 9 CL
was higher (P!0.01) than in day 4 CL (Fig. 7, bottom panel).
Buserelin increased (P!0.01) PGF2a in vitro secretion by both
day 9 and 13 CL (Fig. 7, bottom panel). The co-incubation of
buserelin with antide, compound 48/80, 2-aminoethyl
diphenylborinate, 1-hexadecyl-2-acetyl glycerol, or stauros-
porine counteracted (P!0.01) the effects of buserelin alone
on day 9 and 13 CL (Fig. 7, bottom panel). The co-treatment
with ASA decreased (P!0.01) PGF2a secretion in all CL
types, while the co-treatment withN-nitro-L-arginine methyl
ester did not affect the buserelin-induced PGF2a secretion
(Fig. 7, bottom panel).
Basal in vitroPGE2 secretion was higher in day 4 CL (P!0.01)
than in day 9 and13CL (Fig. 7, middlepanel). Buserelin reduced
(P!0.01) PGE2 in vitro secretion by day 13 CL (Fig. 7, middle
panel). The co-incubation of buserelin with antide, compound
48/80, 2-aminoethyl diphenylborinate, 1-hexadecyl-2-acetyl
glycerol, or staurosporine counteracted (P!0.01) the effects of
buserelin alone on day 13 CL (Fig. 7, middle panel). The
co-treatment with ASA decreased (P!0.01) PGE2 secretion inJournal of Endocrinology (2010) 207, 289–300
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injectionday.Values aremeanGS.D. of six replicates. Asterisks indicate
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Figure 7 In vitro effects of GNRH-I agonist (buserelin, GNRH-I)
alone or co-incubated with antagonists for GNRH-I (antide, GNRH-
Ia), IP3 (2-aminoethyl diphenylborinate, IP3a), and DAG
(1-hexadecyl-2-acetyl glycerol, DAGa), or inhibitors for PLC
(compound 48/80, PLCi), PKC (staurosporine, PKCi), COX (acetyl-
salicylic acid, COXi), and NOS (N-nitro-L-arginine methyl ester,
NOSi) on progesterone (top panel), PGE2 (middle panel), and PGF2a
(bottom panel) release by rabbit CL at days 4, 9, and 13 of
pseudopregnancy. Values are meansGS.D. of five replicates.
Different letters above the bars indicate significantly different values
(P!0.01): Greek letters among control CL days; Latin letters among
experimental groups of the same CL day.
M ZERANI and others . GNRH-I/GNRHR-I system in rabbit CL296all CL types, while the co-treatment with N-nitro-L-arginine
methyl ester did not affect the buserelin-induced PGE2 secretion
(Fig. 7, middle panel).
Enzyme activities Basal COX-1 activity was higher in day
13 CL (P!0.01) than in day 4 and 9 CL (Fig. 8, top panel).
All treatments did not affect COX-1 activity in all CL types,
except for ASA that decreased (P!0.01) the enzymatic
activity (Fig. 8, top panel).
Basal COX-2 activity of day 13 CL was higher (P!0.01)
than that of day 4 and 9 CL; COX-2 activity of day 9 CL was
higher (P!0.01) than that of day 4 CL (Fig. 8, middle panel).
Buserelin increased (P!0.01) COX-2 activity in CL of all
stages (Fig. 8, middle panel). The co-incubation of buserelin
with antide, compound 48/80, 2-aminoethyl diphenylbor-
inate, 1-hexadecyl-2-acetyl glycerol, or staurosporine coun-
teracted (P!0.01) the effects of buserelin alone (Fig. 8,
middle panel). The co-treatments with ASA decreased
(P!0.01) COX-2 activity in all CL types, while the
co-treatments with N-nitro-L-arginine methyl ester did not
affect the buserelin-induced COX-2 activity increase (Fig. 8,
middle panel).
Basal NOS activity of day 4 CL was higher (P!0.01)
than that of day 9 CL (Fig. 8, bottom panel). Buserelin
increased (P!0.01) NOS activity in both day 9 and 13 CL
(Fig. 8, bottom panel). The co-incubation of buserelin with
antide, compound 48/80, 2-aminoethyl diphenylborinate,
1-hexadecyl-2-acetyl glycerol, or staurosporine counteracted
(P!0.01) the effects of buserelin alone at day 9 and 13 (Fig. 8,
bottom panel). The co-treatments with N-nitro-L-arginine
methyl ester decreased (P!0.01) NOS activity in CL of all
stages, while that with ASA in both day 9 and 13 CL (Fig. 8,
bottom panel).
All hormone release and enzyme activity data are
summarized in the synoptic Table 2.Journal of Endocrinology (2010) 207, 289–300 www.endocrinology-journals.org
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Figure 8 In vitro effects of GNRH-I agonist (buserelin, GNRH-I)
alone or co-incubatedwith antagonists for GNRH-I (antide, GNRH-
Ia), IP3 (2-aminoethyl diphenylborinate, IP3a), and DAG (1--
hexadecyl-2-acetyl glycerol, DAGa), or inhibitors for PLC
(compound 48/80, PLCi), PKC (staurosporine, PKCi), COX (acet-
ylsalicylic acid, COXi), and NOS (N-nitro-L-arginine methyl ester,
NOSi) on COX-1 (top panel), COX-2 (middle panel), and NOS
(bottom panel) activities by rabbit CL at days 4, 9, and 13 of
pseudopregnancy. Values are meansGS.D. of five replicates.
Different letters above the bars indicate significantly different values
(P!0.01): Greek letters among control CL days; Latin letters among
experimental groups of the same CL day.
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The present study, for the first time, indicates the presence of
a GNRH/GNRHR system that modulates the steroidogenic
luteal function of pseudopregnant rabbits.www.endocrinology-journals.orgThe first evidence for the presence of ovarian GNRHR,
through ligand-specific binding sites, was observed in rat
granulosa and luteal cells (Reeves et al. 1980, Pieper et al. 1981,
Olofsson et al. 1995). Subsequently, the presence of GNRHR
mRNA was also identified in human granulosa luteal cells
(Kang et al. 2000) and in both follicles and CL of bovine ovary
(Ramakrishnappa et al. 2001). Among the different stages of
CL, GNRHR transcripts were clearly detectable in stage III
luteal tissues, whereas the expression levels were slightly lower
in stage II, and barely or no detectable signal was evident from
stages I and IV luteal tissues (Milvae et al. 1984).
Our study showed the presence of GNRHR-I at both
transcript and protein levels in CL of pseudopregnant rabbits.
Apparently, both mRNA and protein abundances did not
change at different luteal stages, suggesting that in the rabbit
this receptor is not dynamically regulated during the CL
lifespan. In both early- and mid-luteal stages, lutealGNRHR-I,
FSHR, and LHR transcript levels were expressed at
approximately the same relative abundance. By converse, the
GNRHR-I to FSHR or toLHRmRNAs ratio decreased in CL
of late-luteal stage as a consequence of the two- to three-fold
up-regulation of these two ovarian markers. Positive staining
for GNRHR-I was clearly evidenced in the cytoplasm of
luteal cells during all stages of pseudopregnancy.
The presence of GNRH-I has been revealed in the ovary
of rats (Aten et al. 1986, Schirman-Hildelsheim et al. 2005,
Sengupta et al. 2008), monkeys (Chakrabarti et al. 2008), and
humans (Aten et al. 1987). The present investigation confirms
that also the ovary of rabbits expresses GNRH-I in the
cytoplasm of different cell types, including the luteal cells,
independently of the luteal stage examined.
The presence of GNRHR-I and GNRH-I, similarly to
what found in other species, supports a direct role of GNRH in
the regulation of luteal functions in rabbits. GNRHR-I
immunoreactivity was also observed in other rabbit ovary cells
as oocytes, follicular and thecal cells, so stressing the potential
paracrine and/or autocrine role of the GNRH/GNRHR
system in modulating ovary function in mammals
(Ramakrishnappa et al. 2005). Interestingly, in the early-luteal
stage, the microdensitometry results revealed the presence
of larger GNRHR-I amounts in luteal than in follicle
cells suggesting that GNRH-I is involved also in the
luteotropic processes.
GNRH has been shown to exert a mixture of both
inhibitory and stimulatory effects in the gonads, causing either
inhibitory or stimulatory effects on ovarian cellular steroid
output (Ramakrishnappa et al. 2005). In bovine, two GNRH
antagonists, buserelin and deslorelin, showed in vivo and
in vitro inhibitory effects on progesterone release (Milvae et al.
1984, D’Occhio & Aspden 1999). Conversely, GNRH
stimulatory in vitro effects on progesterone production were
demonstrated in monkey and human granulosa cells (Casper
et al. 1984, Liu et al. 1991, Bussenot et al. 1993). Finally, other
authors documented that GNRH has no effect on pro-
gesterone production in human granulosa–lutein cells (Casper
et al. 1984). In rabbits, GNRH agonist directly affected theJournal of Endocrinology (2010) 207, 289–300
Table 2 In vitro effects of GNRH-I agonist (buserelin, GNRH-I) alone or co-incubated with antagonists for GNRH-I (antide, GNRH-Ia), IP3
(2-aminoethyl diphenylborinate, IP3a), and DAG (1-hexadecyl-2-acetyl glycerol, DAGa), or inhibitors for PLC (compound 48/80, PLCi), PKC
(staurosporine, PKCi), COX (acetylsalicylic acid, COXi), and NOS (N-nitro-L-arginine methyl ester, NOSi) on progesterone, PGE2, and PGF2a
release and COX-1, COX-2, and NOS activities by rabbit CL at days 4, 9, and 13 of pseudopregnancy. Values are meansGS.D. of five replicates
Progesterone PGF2a PGE2 COX-1 COX-2 NOS
Day 4
Control 1997G273aa 707G225aa 796G200aa 7859G1135aa 3145G825aa 19 202G1702aa
GNRH-I 1755G152a 640G167a 860G105a 6728G1178a 9705G2101b 18 910G1613a
GNRH-ICGNRH-Ia 1671G336a 702G172a 899G358a 6264G2667a 3478G492a 17 096G4393a
GNRH-ICPLCi 2099G248a 597G112a 699G158a 7030G1912a 3044G508a 16 475G1788a
GNRH-ICIP3a 2280G332
a 715G183a 899G140a 8152G1881a 2587G437a 20 172G3336a
GNRH-ICDAGa 1860G389a 627G114a 785G187a 7961G803a 3219G567a 17 438G2315a
GNRH-ICPKCi 2001G305a 617G152a 725G247a 7526G1640a 2746G305a 18 762G3655a
GNRH-ICCOXi 1696G371a 133G47b 137G47b 537G323b 372G252c 18 472G2255a
GNRH-ICNOSi 1947G317a 637G185a 899G184a 6509G2542a 9497G1072b 1246G340b
Day 9
Control 5197G383ab 2089G297ab 161G71ab 7220G1855aa 8116G1830ab 14 212G2764ab
GNRH-I 2048G240b 3825G346b 103G44a 7442G1505a 41 452G5559b 35 421G4201b
GNRH-ICGNRH-Ia 5479G1693a 2170G447a 179G50a 8013G962a 6472G2044a 15 608G3236b
GNRH-ICPLCi 4851G394a 1842G160a 174G32a 8135G1197a 8135G1094a 14 197G2369b
GNRH-ICIP3a 4458G452
a 2051G536a 181G19a 7061G1073a 7213G1241a 19 971G5048b
GNRH-ICDAGa 4708G250a 1825G431a 191G27a 8048G951a 6956G1586a 15 230G3553b
GNRH-ICPKCi 4580G664a 2107G133a 162G39a 6053G1139a 8237G1039a 15 246G4083b
GNRH-ICCOXi 7604G633c 202G27c 78G10b 767G197b 318G144c 7065G1667c
GNRH-ICNOSi 7919G558c 4343G521b 205G52a 6436G3051a 43 295G5218b 1158G304d
Day 13
Control 3789G182ag 3304G245ag 248G46ab 16 440G5308ab 26 599G4624ag 17 549G950aab
GNRH-I 1894G176b 4614G266b 113G37b 16 636G5068a 45 060G3325b 36 432G3697b
GNRH-ICGNRH-Ia 3680G877a 2768G485a 255G97a 15 640G2021a 24 809G3494a 17 212G4669a
GNRH-ICPLCi 3922G356a 2819G492a 272G47a 18 757G4722a 23 776G4026a 17 616G1326a
GNRH-ICIP3a 4165G434
a 2816G296a 247G41a 18 126G3678a 27 674G5558a 20 435G2380a
GNRH-ICDAGa 3850G391a 3104G262a 268G31a 19 989G2879a 26 756G4166a 18 426G1684a
GNRH-ICPKCi 3892G576a 2981G369a 282G60a 20 608G3325a 31 061G2442a 18 326G5029a
GNRH-ICCOXi 6108G613c 185G34c 86G31b 796G482b 292G71c 5640G1982c
GNRH-ICNOSi 6161G693c 4922G366b 261G70a 15 182G3319a 40 792G4471b 963G164d
Different letters indicate significantly different values (P!0.01): Greek letters among control CL days; Latin letters among experimental groups of the same CL day.
M ZERANI and others . GNRH-I/GNRHR-I system in rabbit CL298ovary by inducing ovulation in both hypophysectomized
animals and in vitro perfused system (Koos & LeMaire 1985).
At day 11 of pseudopregnancy, GNRH injection induced
luteinization of ovarian follicles and functional regression of
CL as assessed by decline in serum progesterone levels within
3 days (Rippel et al. 1976). Depending on the dosage
administered between days 8 and 13 of gestation, GNRH was
found to either cause abortion by luteolysis or support fetal
survival by stimulating luteotropic activity (Eisenberg et al.
1984). Conversely, other authors found that GNRH did not
exhibit any direct inhibitory effect on steroid production in
extracorporeal perfused ovary (Eisenberg et al. 1984).
Our data strengthen the idea that GNRH-I has a direct
role in the down-regulation of rabbit CL progesterone
production. The in vitro experiments showed that buserelin
reduced progesterone production by cultured CL collected at
days 9 and 13 of pseudopregnancy, whereas this steroid
synthesis was not affected by GNRH-I agonist in day 4 CL. In
addition, this GNRH-I role is also supported by the data of
the co-incubation with antide, a GNRH-I antagonist, that
counteracted the buserelin-induced progesterone decrease.Journal of Endocrinology (2010) 207, 289–300The in vivo experiments mirrored the above-reported in vitro
data; in fact, blood progesterone levels were down-regulated
when buserelin was administered at mid- and late-pseudo-
pregnancy. Even if we cannot exclude that this in vivo
buserelin-induced circulating progesterone decrease is also
caused by a pituitary gonadotropin down-regulation,
the in vivo and in vitro coincident lack of buserelin effects
during early-pseudopregnancy suggests that this progesterone
decline is primarily or exclusively due to the direct action of
GNRH-I agonist on pseudopregnant CL.
Recently, we demonstrated, through in vitro studies on CL
of pseudopregnant rabbits, that PGF2a and PGE2 affect
progesterone release differently, depending on the luteal
stage (Boiti et al. 2001). PGE2 depressed NOS activity and
increased progesterone production in day 4 CL but was totally
ineffective in day 9 CL; on the contrary, PGF2a up-regulated
NOS activity and induced functional luteolysis in day 9 CL but
had no effect on CL collected at the early-luteal phase. This
physiological mechanism protects the growing CL from
functional luteolysis to occur in the early-luteal stage until
day 6 of pseudopregnancy, when CL shift from refractorinesswww.endocrinology-journals.org
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Figure 9 Schematic representation of the suggested GNRH-I post-
receptorial mechanism regulating the progesterone production in
rabbit CL. The hatched lines represent other possible PKC target(s).
AA, arachidonic acid; COX-2, cyclo-oxygenase-2; DAG, diacyl-
glycerol; GNRHR-I, type I GNRH receptor; IP3, inositol trispho-
sphate; NO, nitric oxide; NOS, nitric oxide synthase; PGE2,
prostaglandin E2; PGE2-9-K, prostaglandin E2-9-ketoreductase;
PGF2a, prostaglandin F2a; PGFS, prostaglandin F2a synthase; PGH2,
prostaglandin H2; PIP2, phosphatidylinositol diphosphate; PKC,
protein kinase C; PLC, phospholipase C. Full colour version of
this figure available via http://dx.doi.org/10.1677/JOE-10-0109.
GNRH-I/GNRHR-I system in rabbit CL . M ZERANI and others 299to partial responsiveness to exogenous PGF2a, and acquire
luteolytic competence (Boiti et al. 1998, 2001, 2003). The data
on the buserelin ineffectiveness at early-luteal stage suggest
that this luteolytic-protecting mechanism includes also the
GNRH-I/GNRHR-I system, at least in vitro.
Many studies indicate that GNRH, complexing with
cognate receptor, mainly activates PLC via Gq/11 family G
proteins. PLC catalyzes the hydrolysis of phosphatidylinositol
4,5-bisphosphate to IP3 and DAG (Millar 2005). Our data
confirmed that this GNRH post-receptorial mechanism is
present also in the rabbit CL. In fact, the effects of buserelin in
decreasing progesterone release on day 9 and 13 CL were
counteracted by the co-incubation with PLC and PKC
inhibitors or IP3 and DAG antagonists, while the inhibitors of
AC, PLA2, and PLD had no influences.
A recent study showed that in the gonadotrope cell line
LbT2, GNRH produced a marked time-dependent
induction of COX-2 expression and an increase in PGE2
and PGF2a production (Naor et al. 2007). These authors
hypothesize a novel GNRH signaling pathway mediated by
PGF2a, which acts through an autocrine/paracrine modality.
The present work suggests that the GNRH-I effects on rabbitwww.endocrinology-journals.orgCL progesterone production are mediated by the activation of
the COX-2/PGF2a/NOS pathway. In fact, buserelin
increased in vitro COX-2 activity, PGF2a production, and
NOS activity in both day 9 and 13 CL, coinciding with
decreasing progesterone release. In addition, the co-treatment
with antide, PLC and PKC inhibitors, or IP3 and DAG
antagonists counteracted the buserelin actions on COX-2,
PGF2a, NOS, and progesterone, while COX inhibitor
counteracted those on NOS and progesterone, and, in turn,
NOS inhibitor counteracted those on progesterone only. The
decrease in PGE2 induced by buserelin in day 13 CL is
probably due to the increased conversion of this PG into
PGF2a through PGE2-9-ketoreductase enzyme activation
and/or the inactivation of PGE2 synthase. A similar
intracellular mechanism was reported for the PGF2a auto-
amplifying loop utilized by the rabbit CL during the
luteolytic process (Zerani et al. 2007). Our results also
indicated that early CL refractoriness to luteolytic factors
extends to GNRH-I as well, given that the all in vitro effects of
buserelin on hormone productions and enzymatic activities
occur only in day 9 and 13 CL.
In conclusion, this study provides the evidence that
GNRH-I, in autocrine, paracrine, and/or endocrine manner,
directly down-regulates progesterone production in rabbit CL
that have acquired luteolytic competence, with a receptorial/
post-receptorial mechanism as summarized in Fig. 9. GNRH-I
couples its cognate type I receptor activating PLC and, in turn,
releasing IP3 and DAG; these two intracellular messengers,
through the PKC activation, start up COX-2 activity, with the
consequent rise of PGF2a production; this PG induces (via
paracrine, autocrine, and/or intracrine mechanism) an increase
in NOS activity (Boiti et al. 2003); finally NO down-regulates
progesterone levels (Boiti et al. 2000).
However, though the present data throw new light on the
knowledge of the physiological mechanisms regulating luteal
activity, further studies are needed to better understand the
GNRH/GNRHR system fine-tuning that controls rabbit
CL life span, including the presence of type II GNRHR or
the involvement of PGF2a synthase and PGE2-9-ketoreduc-
tase, key enzymes of the PGF2a synthesis.Declaration of interest
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